SELLAS Life Sciences Group (NASDAQ:SLS) Reaches New 52-Week High – Time to Buy?

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) hit a new 52-week high during trading on Thursday . The stock traded as high as $9.70 and last traded at $9.91, with a volume of 1591746 shares traded. The stock had previously closed at $9.17.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on SLS shares. Maxim Group boosted their target price on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, March 12th. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.00.

SELLAS Life Sciences Group Price Performance

The firm has a fifty day simple moving average of $6.88 and a 200-day simple moving average of $5.04. The firm has a market cap of $2.10 billion, a P/E ratio of -46.57 and a beta of 2.50.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in SELLAS Life Sciences Group by 2.8% in the 3rd quarter. Vanguard Group Inc. now owns 6,839,905 shares of the company’s stock valued at $11,012,000 after acquiring an additional 185,106 shares in the last quarter. Anson Funds Management LP raised its stake in shares of SELLAS Life Sciences Group by 2,093.8% in the third quarter. Anson Funds Management LP now owns 6,032,938 shares of the company’s stock worth $9,713,000 after purchasing an additional 5,757,938 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of SELLAS Life Sciences Group by 35.9% in the fourth quarter. Geode Capital Management LLC now owns 3,077,337 shares of the company’s stock worth $11,604,000 after purchasing an additional 812,953 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of SELLAS Life Sciences Group by 23,550.0% in the second quarter. Marshall Wace LLP now owns 2,715,489 shares of the company’s stock valued at $5,947,000 after purchasing an additional 2,704,007 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of SELLAS Life Sciences Group by 60.8% in the fourth quarter. State Street Corp now owns 2,188,171 shares of the company’s stock valued at $8,249,000 after purchasing an additional 827,257 shares in the last quarter. 17.38% of the stock is owned by institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.